Tivdak® (tisotumab vedotin-tftv) significantly prolonged overall survival in patients with recurrent or metastatic cervical cancer compared with chemotherapy in global phase 3 innovatv 301 trial
Media release tivdak demonstrated statistically significant overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented at esmo 2023 congress results from innovatv 301 intended to serve as pivotal confirmatory trial for u.s. accelerated approval and to support global regulatory applications copenhagen, denmark, and bothell, wash.; october 22, 2023 – genmab a/s (nasdaq: gmab) and seagen inc. (nasdaq: sgen) announced additional results today from the phase 3 innovatv 301 randomized global trial, which showed treatment with tivdak demonstrated a statistically significant and clinically meaningful 30 percent reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, compared with chemotherapy (hr: 0.70, 95 percent ci: 0.54-0.89, p=0.0038i).
SGEN Ratings Summary
SGEN Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission